• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Vaccines . Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes

tetano

Editor, Senior Moderator
NPJ Vaccines


. 2026 Apr 25.
doi: 10.1038/s41541-026-01464-2. Online ahead of print.
Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes

Shintaro Oishi[SUP] #[/SUP][SUP] 1 2 [/SUP], Ryutaro Kotaki[SUP] #[/SUP][SUP] 3 4 [/SUP], Hisham M Dokainish[SUP] #[/SUP][SUP] 1 [/SUP], Saya Moriyama[SUP] 1 [/SUP], Shinichiro Ota[SUP] 5 [/SUP], Takayuki Matsumura[SUP] 1 [/SUP], Tomohiro Takano[SUP] 1 [/SUP], Taishi Onodera[SUP] 1 [/SUP], Yu Adachi[SUP] 1 [/SUP], Kazutaka Terahara[SUP] 1 [/SUP], Masanori Isogawa[SUP] 6 [/SUP], Kazuhiko Katayama[SUP] 2 [/SUP], Takashi Sato[SUP] 5 7 [/SUP], Masaharu Shinkai[SUP] 8 [/SUP], Yoshimasa Takahashi[SUP] 9 [/SUP]


Affiliations
Free article Abstract

Receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike contains multiple classes of antibody epitopes that are associated with diverse neutralizing activities. Although both natural infection and vaccination robustly elicit RBD-reactive and neutralizing antibodies, the spike antigenic structures presented to the immune system may differ, leading to qualitative differences in the antibody responses. Using large and well-controlled cohorts, we show that the neutralizing potency index (NPI), calculated as the ratio of neutralizing titer to RBD IgG titer, is approximately fivefold lower in vaccine recipients than in convalescent individuals, independent of disease severity, comorbidities, or demographic factors. This reduction in NPI is associated with enhanced antibody targeting to non-neutralizing, yet conserved and structurally occluded RBD epitope. Molecular dynamics (MD) simulations together with the binding assay demonstrate that the occluded epitope is allosterically exposed by stabilizing mutations introduced into the vaccine spike antigen, a process mediated by a highly extended RBD-up conformation. Collectively, our findings demonstrate that RBD conformational modulation by stabilizing mutations shapes vaccine antigenicity and likely alters the epitope landscape of antibody responses.


 
Back
Top Bottom